Literature DB >> 33322372

Dissolution Enhancement and Controlled Release of Paclitaxel Drug via a Hybrid Nanocarrier Based on mPEG-PCL Amphiphilic Copolymer and Fe-BTC Porous Metal-Organic Framework.

Nikolaos D Bikiaris1, Nina Maria Ainali1, Evi Christodoulou1, Margaritis Kostoglou2, Thomas Kehagias3, Emilia Papasouli4, Emmanuel N Koukaras4, Stavroula G Nanaki1.   

Abstract

In the present work, the porous metal-organic framework (MOF) Basolite®F300 (Fe-BTC) was tested as a potential drug-releasing depot to enhance the solubility of the anticancer drug paclitaxel (PTX) and to prepare controlled release formulations after its encapsulation in amphiphilic methoxy poly(ethylene glycol)-poly(ε-caprolactone) (mPEG-PCL) nanoparticles. Investigation revealed that drug adsorption in Fe-BTC reached approximately 40%, a relatively high level, and also led to an overall drug amorphization as confirmed by differential scanning calorimetry (DSC) and X-ray diffraction (XRD). The dissolution rate of PTX-loaded MOF was substantially enhanced achieving a complete (100%) release within four days, while the neat drug only reached a 13% maximum rate (3-4 days). This PTX-Fe-BTC nanocomposite was further encapsulated into a mPEG-PCL matrix, a typical aliphatic amphiphilic copolyester synthesized in our lab, whose biocompatibility was validated by in vitro cytotoxicity tests toward human umbilical vein endothelial cells (HUVEC). Encapsulation was performed according to the solid-in-oil-in-water emulsion/solvent evaporation technique, resulting in nanoparticles of about 143 nm, slightly larger of those prepared without the pre-adsorption of PTX on Fe-BTC (138 nm, respectively). Transmission electron microscopy (TEM) imaging revealed that spherical nanoparticles with embedded PTX-loaded Fe-BTC nanoparticles were indeed fabricated, with sizes ranging from 80 to 150 nm. Regions of the composite Fe-BTC-PTX system in the infrared (IR) spectrum are identified as signatures of the drug-MOF interaction. The dissolution profiles of all nanoparticles showed an initial burst release, attributed to the drug amount located at the nanoparticles surface or close to it, followed by a steadily and controlled release. This is corroborated by computational analysis that reveals that PTX attaches effectively to Fe-BTC building blocks, but its relatively large size limits diffusion through crystalline regions of Fe-BTC. The dissolution behaviour can be described through a bimodal diffusivity model. The nanoparticles studied could serve as potential chemotherapeutic candidates for PTX delivery.

Entities:  

Keywords:  Fe-BTC; controlled release; dissolution enhancement; mPEG-PCL copolymer; metal-organic framework; nanoparticles; paclitaxel; quantum chemistry; tight binding

Year:  2020        PMID: 33322372      PMCID: PMC7763675          DOI: 10.3390/nano10122490

Source DB:  PubMed          Journal:  Nanomaterials (Basel)        ISSN: 2079-4991            Impact factor:   5.076


  46 in total

1.  Mitochondria-based biosensors with piezometric and RELS transduction for potassium uptake and release investigations.

Authors:  Magdalena Stobiecka; Slawomir Jakiela; Agata Chalupa; Piotr Bednarczyk; Beata Dworakowska
Journal:  Biosens Bioelectron       Date:  2016-07-30       Impact factor: 10.618

2.  Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers.

Authors:  Heike Friedrich; Bernd Fussnegger; Karl Kolter; Roland Bodmeier
Journal:  Eur J Pharm Biopharm       Date:  2005-11-04       Impact factor: 5.571

3.  Ternary Interactions and Energy Transfer between Fluorescein Isothiocyanate, Adenosine Triphosphate, and Graphene Oxide Nanocarriers.

Authors:  Katarzyna Ratajczak; Magdalena Stobiecka
Journal:  J Phys Chem B       Date:  2017-07-05       Impact factor: 2.991

4.  PEGylated lipid bilayer coated mesoporous silica nanoparticles co-delivery of paclitaxel and curcumin leads to increased tumor site drug accumulation and reduced tumor burden.

Authors:  Jiafeng Gao; Kai Fan; Yipeng Jin; Linna Zhao; Qian Wang; Yinian Tang; Huihao Xu; Zhongjie Liu; Shuaiyu Wang; Jiahao Lin; Degui Lin
Journal:  Eur J Pharm Sci       Date:  2019-09-10       Impact factor: 4.384

5.  Novel self-assembled core-shell nanoparticles based on crystalline amorphous moieties of aliphatic copolyesters for efficient controlled drug release.

Authors:  Sofia Papadimitriou; Dimitrios Bikiaris
Journal:  J Control Release       Date:  2009-05-14       Impact factor: 9.776

6.  Paclitaxel and quercetin co-loaded functional mesoporous silica nanoparticles overcoming multidrug resistance in breast cancer.

Authors:  Mengyao Liu; Manfei Fu; Xiaoye Yang; Guoyong Jia; Xiaoqun Shi; Jianbo Ji; Xianghong Liu; Guangxi Zhai
Journal:  Colloids Surf B Biointerfaces       Date:  2020-07-29       Impact factor: 5.268

7.  Localized delivery of active targeting micelles from nanofibers patch for effective breast cancer therapy.

Authors:  Sivaraj Mehnath; Karuppannan Chitra; Kandhasamy Karthikeyan; Murugaraj Jeyaraj
Journal:  Int J Pharm       Date:  2020-05-11       Impact factor: 5.875

8.  Bone interface modulates drug resistance in breast cancer bone metastasis.

Authors:  Sumanta Kar; Dinesh R Katti; Kalpana S Katti
Journal:  Colloids Surf B Biointerfaces       Date:  2020-06-26       Impact factor: 5.268

9.  Chitosan-coated mesoporous MIL-100(Fe) nanoparticles as improved bio-compatible oral nanocarriers.

Authors:  T Hidalgo; M Giménez-Marqués; E Bellido; J Avila; M C Asensio; F Salles; M V Lozano; M Guillevic; R Simón-Vázquez; A González-Fernández; C Serre; M J Alonso; P Horcajada
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

10.  Preparation and characterization of Alendronate depot microspheres based on novel poly(-ε-caprolactone)/Vitamin E TPGS copolymers.

Authors:  Christina Koulouktsi; Stavroula Nanaki; Panagiotis Barmpalexis; Margaritis Kostoglou; Dimitrios Bikiaris
Journal:  Int J Pharm X       Date:  2019-04-25
View more
  3 in total

1.  Pegylated-polycaprolactone nano-sized drug delivery platforms loaded with biocompatible silver(i) complexes for anticancer therapeutics.

Authors:  Despoina Varna; Evi Christodoulou; Eleni Gounari; Chrysanthi Pinelopi Apostolidou; Georgios Landrou; Rigini Papi; George Koliakos; Athanassios G Coutsolelos; Dimitrios N Bikiaris; Panagiotis A Angaridis
Journal:  RSC Med Chem       Date:  2022-05-26

2.  Combined Shikonin-Loaded MPEG-PCL Micelles Inhibits Effective Transition of Endothelial-to-Mesenchymal Cells.

Authors:  Guanglin Li; Chenxu Shang; Qingqing Li; Lifang Chen; Zejun Yue; Lingxuan Ren; Jianjun Yang; Jiye Zhang; Weirong Wang
Journal:  Int J Nanomedicine       Date:  2022-09-24

3.  Programmable Drug Release from a Dual-Stimuli Responsive Magnetic Metal-Organic Framework.

Authors:  Muhammad Usman Akbar; Muhammad Badar; Muhammad Zaheer
Journal:  ACS Omega       Date:  2022-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.